Clinical Trial

Tocotrienol Against the Progression of End Stage Liver Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis. The study is double blind and participants will be randomized to take 2 capsules of TCT (200mg) or placebo twice a day for 3 years.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2015-10-16; most recent amendment 2026-02-04.
Status change: Recruiting → Active, Not Recruiting 2024-09-03
Status change: Not Yet Recruiting → Recruiting 2016-05-03
Trial Details
NCT Number NCT02581085
Lead Sponsor Chandan Sen
Collaborators: Malaysia Palm Oil Board, Indiana University
Conditions End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Enrollment 70 participants
Start Date 2019-11-01
Primary Completion 2026-12-16 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09